FluoGuide receives FDA fast track designation for FG001 in high grade glioma

18 March 2026 - FluoGuide announces that the US FDA has granted fast track designation to FG001 as an intra-operative imaging ...

Read more →

Polaryx Therapeutics receives FDA fast track designation for PLX‑200 for late‑infantile neuronal ceroid lipofuscinosis

17 March 2026 - Regulatory milestone supports advancement of the SOTERIA Phase 2 basket trial evaluating PLX‑200 across multiple lysosomal storage ...

Read more →

Argo Biopharma receives FDA fast track designation for BW-20805, an investigational siRNA therapy for the treatment of HAE

16 March 2026 - Global Phase 2 open-label study in adult hereditary angioedema patients on-going, company on track for primary completion ...

Read more →

ARTHEx Biotech granted FDA fast track designation for ATX-01 for the treatment of myotonic dystrophy type 1

11 March 2026 - ARTHEx Biotech today announced that the US FDA has granted fast track designation to ATX-01 for the ...

Read more →

Quoin Pharmaceuticals announces FDA grants fast track designation for QRX003 for the treatment of Netherton syndrome

11 March 2026 - Quoin Pharmaceuticals today announced that the US FDA has granted fast track designation to QRX003 lotion (4%) ...

Read more →

Redx’s RXC008 granted US FDA fast track designation for fibrostenotic Crohn’s disease

10 March 2026 - Redx Pharma announces that the US FDA has granted fast track designation to RXC008, a GI ...

Read more →

Precision BioSciences receives FDA fast track sesignation for PBGENE-DMD

9 March 2026 - Precision BioSciences today announced that the US FDA has granted fast track designation to PBGENE-DMD for the ...

Read more →

Affinia Therapeutics granted FDA fast track designation for AFTX-201 as a treatment for people living with BAG3-associated dilated cardiomyopathy

4 March 2026 - Affinia Therapeutics today announced that the US FDA has granted fast track designation for AFTX-201, a potential ...

Read more →

Johnson & Johnson therapy nipocalimab granted US FDA fast track designation in systemic lupus erythematosus

3 March 2026 - Johnson & Johnson today announced that nipocalimaba was granted US FDA fast track designation as a potential ...

Read more →

Siren Biotechnology receives FDA fast track designation for SRN-101 for the treatment of recurrent high grade glioma

24 February 2026 - Siren Biotechnology today announced that the US FDA has granted fast track designation to SRN-101, the ...

Read more →

Aktis Oncology receives US FDA fast track designation for AKY-1189, a nectin-4 miniprotein radioconjugate

24 February 2026 - Aktis Oncology today announced that the US FDA has granted fast track designation to AKY-1189 for the ...

Read more →

Artios receives US FDA fast track designation for DNA polymerase theta inhibitor ART6043 for treatment of gBRCA-mutated HER2 negative breast cancer

23 February 2026 - Artios Pharma today announced that the US FDA granted fast track designation to its potentially first ...

Read more →

Tessera Therapeutics receives US FDA fast track and orphan drug designations for its lead in vivo gene editing program TSRA-196 for the treatment of adults with AATD

23 February 2026 - Tessera Therapeutics today announced that the US FDA has granted fast track and orphan drug designations to ...

Read more →

Pilatus Biosciences receives FDA fast track designation for metabolic checkpoint inhibitor PLT012 in hepatocellular carcinoma

19 February 2026 - Pilatus Biosciences today announced that the US FDA has granted fast track designation for PLT012, the ...

Read more →

99mTc-maraciclatide granted FDA fast track designation for the visualisation of inflammation in interstitial lung disease

12 February 2026 -  Serac Healthcare announced today that the US FDA has granted fast track designation to 99mTc-maraciclatide as ...

Read more →